Ensayos clínicos A continuación, se enumeran los ensayos clínicos actuales.51 estudios en Programa de tumores cerebrales (solo estudios abiertos). Filtra esta lista de estudios por sede, estatus, etc. A Study to Evaluate the Surgical Removal of Residual Brain Tumors Prior to Recurrence Rochester, Minn. The purpose of this study is to evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. Eligible patients with surgically accessible latent tumors desiring surgical resection will be enrolled to prospectively track short- and long-term outcomes. Safety will be evaluated by quantifying rates of surgical morbidity as compared to patients undergoing RT after surgery, or no surgery for similar latent disease. Variables evaluated will include postoperative complications including death within 30 days, wound infection, length of hospital stay, and readmission rates. Ommaya Placement for Biomarker Collection Rochester, Minn. The purpose of this study is to determine the safety and feasibility of intra-operative Ommaya Reservoir placement during a clinically indicated tumor surgery in order to facilitate a longitudinal access to cerebrospinal fluid (CSF) for analysis of exploratory and future tumor biomarkers for individualized monitoring. A Study to Determine the Best Individualized Cancer Therapy Using Circulating Tumor DNA (ctDNA) in Patients with GI, CNS, and Thoracic Cancers. Jacksonville, Fla. This study proposes to develop and maintain a biorepository of blood samples collected from patients receiving definitive chemoradiotherapy for locally advanced rectal cancer, locally advanced pancreatic cancer, non-small cell lung cancer, or cervical cancer. The ultimate goal of this biorepository will be to provide the resource to initiate an exploration of ctDNA as a potential liquid biopsy for GI and Thoracic malignancy detection and surveillance. A Study to Compare Optimal MRI Timing for Pre-surgical Planning to LINAC-based Therapy Rochester, Minn. The purpose of this research is to compare two different standard-of-care pre-surgical imaging methods. A Study to Evaluate Endoscopic Endonasal Skull Base Surgery and Pituitary Surgery Quality of Life Rochester, Minn. The objectives of this study are to: Measure the short and long-term overall and nasal-specific quality of life (QOL) impact of patients undergoing Endoscopic Endonasal Skull Base Surgery (EESBS) for pituitary and sellar lesions. Determine the relative difference in QOL impact of EESBS for patients undergoing surgery for functional and nonfunctional pituitary adenomas. Generate baseline data to development and validate a site-specific endoscopic-specific comprehensive QOL for EESBS. Particular tumors of interest include pituitary tumors, Rathke’s cleft cysts, craniopharyngiomas, clival chordomas and chondrosarcomas. Specific QOL aims focus on olfaction (sense of smell), gustation (sense of taste) and nasal function. A Study to Analyze NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with temozolomide (TMZ) in patients with diffuse gliomas at first relapse (Phase I), and to determine the antitumor effectiveness of the combination of NMS-03305293 and TMZ in patients with isocitrate dehydrogenase (IDH) wild type glioblastoma at first relapse as measured by the 6-month Progression Free Survival (PFS) rate (Phase II). A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of WSD0922-FU Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and CNS metastases of non-small cell lung cancer (NSCLC). Effect of Agent Orange Exposure on Endocrine Tumor Aggressiveness Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The intent is to collect relevant clinical data on patients exposed to Agent Orange plus assessment of the tissue for genetic mutations known to be associated with growth of thyroid cancer and pituitary tumors and report our findings as a descriptive case series. Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma Rochester, Minn. The purpose of this study is to determine the response rate to the combination of pembrolizumab and NT-I7 in patients with recurrent glioblastoma. Human Blood and Tissues Repository for Neuroscience Research Jacksonville, Fla. The purpose of this study is to collect adult human blood, cerebrospinal fluid, brain, and spine tissues/fluids at time of surgery in order to conduct future studies of the cellular mechanisms of tissue invasion utilized by brain and spine tumors of the central nervous system (CNS). Numeración de páginas Estudios clínicos Ir a página 11 Ir a página 22 Ir a página 33 Ir a página 44 Ir a página 55 SiguientePróxima página Solicite una consulta Pericia & clasificacionesInvestigación June 15, 2024 Comparte en: FacebookTwitter U.S. News & World Report reconoce a Mayo Clinic de Rochester (Minnesota), Mayo Clinic de Phoenix y Scottsdale (Arizona) y Mayo Clinic de Jacksonville (Florida) entre los mejores hospitales del país para neurología y neurocirugía en el período 2024-2025. Obtén más información sobre este gran honor Programa de tumores cerebralesPágina inicialdel departamentoSeccionesSolicita una cita médicaPanorama generalAnálisis y procedimientosEnfermedades que se tratanMédicosMédicos por sede y especialidadGrupos especializadosPericia & clasificacionesEnsayos clínicosInvestigaciónCostos & seguro médicoNoticias de Mayo ClinicRemisiones Investigación: los pacientes son la prioridad Mostrar la transcripción Para video Investigación: los pacientes son la prioridad [SUENA MÚSICA] Dr. Joseph Sirven, profesor de Neurología, Mayo Clinic: La misión de Mayo se centra en el paciente. La prioridad es el paciente. Aquí, la misión y la investigación se hacen para progresar en la forma de ayudar mejor al paciente y para asegurarnos de que el paciente sea la prioridad en la atención médica. De muchas maneras, esto equivale a un ciclo. Puede comenzar con algo tan simple como una idea que se desarrolla en un laboratorio, se traslada a la atención directa del paciente y, si todo sale bien y resulta útil o beneficioso, pasa a ser el método estándar. Creo que una de las características tan singulares de la forma de investigar en Mayo es la concentración en el paciente, y es lo que realmente le ayuda a captar la atención de todos. SeccionesSolicita una cita médicaPanorama generalAnálisis y procedimientosEnfermedades que se tratanMédicosMédicos por sede y especialidadGrupos especializadosPericia & clasificacionesEnsayos clínicosInvestigaciónCostos & seguro médicoNoticias de Mayo ClinicRemisiones ORG-20439710 Centros y departamentos médicos Programa de tumores cerebrales